Jay C. Vance
@jaycvance.bsky.social
Cardiology fellow by way of med-peds
The year is 2032. SpaceX has opened a residential colony on the moon and is now handing out free lattes at the center of the vendor fair at ACC32. This recommendation appears in the new HF guidelines based on a recent JAMA Cardiology research letter. #cardiosky
December 16, 2024 at 9:36 PM
The year is 2032. SpaceX has opened a residential colony on the moon and is now handing out free lattes at the center of the vendor fair at ACC32. This recommendation appears in the new HF guidelines based on a recent JAMA Cardiology research letter. #cardiosky
Hear me out. Find pacer-dependent pts w/ insomnia. Program sleep mode to drop to 30bpm as they fall asleep. Use motion response to determine deep sleep and up rate to 60bpm. When motion increases more (ie morning getting out of bed), up to 100bpm for 30 min to promote wakefulness. #cardiosky #EPeeps
December 15, 2024 at 12:12 AM
Hear me out. Find pacer-dependent pts w/ insomnia. Program sleep mode to drop to 30bpm as they fall asleep. Use motion response to determine deep sleep and up rate to 60bpm. When motion increases more (ie morning getting out of bed), up to 100bpm for 30 min to promote wakefulness. #cardiosky #EPeeps
How does ASE justify this price jump? I want my decision regarding timing of echo boards to be carefully measured based on my acquired competency, family situation, etc, not rushed because the price is increasing by $200 at an arbitrary early deadline.
December 1, 2024 at 10:24 PM
How does ASE justify this price jump? I want my decision regarding timing of echo boards to be carefully measured based on my acquired competency, family situation, etc, not rushed because the price is increasing by $200 at an arbitrary early deadline.
1/ I’m worried about this trial, how it will be spun by Novartis’s brilliant marketing team, and the potential for cripplingly expensive indication creep.
Effects of Sacubitril/Valsartan on Prevention of Cardiotoxicity in High-Risk Patients Undergoing Anthracycline Chemotherapy - American College of Cardiology
Amit Saha, MD
www.acc.org
November 20, 2024 at 1:31 AM
1/ I’m worried about this trial, how it will be spun by Novartis’s brilliant marketing team, and the potential for cripplingly expensive indication creep.
The maverick in me is going to start using trandolapril for AMI with new LV dysfunction. TRACE had a more impressive ACM point estimate than SAVE or GISSI-3 and is more generalizable than AIRE.
November 13, 2024 at 6:23 PM
The maverick in me is going to start using trandolapril for AMI with new LV dysfunction. TRACE had a more impressive ACM point estimate than SAVE or GISSI-3 and is more generalizable than AIRE.